Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic

Updated 06/21/2024

Status Active, not recruiting

Clinical Trial Summary

This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02617849
Study type	Interventional
Source	Jewish General Hospital
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	May 19, 2016
Completion date	December 2025

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00533702` - A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma	Phase 2
	Terminated	`NCT00304200` - Temodar and Sutent as Therapy for Melanoma	Phase 1/Phase 2
	Completed	`NCT01654692` - A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma	Phase 2
	Completed	`NCT02350972` - Inducing Systemic Immunity and Regressions in Metastatic Melanoma	Phase 1
	Terminated	`NCT01705392` - Bevacizumab vs Dacarbazine in Metastatic Melanoma	Phase 2
	Completed	`NCT00625768` - Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma	Phase 1
	Terminated	`NCT00961844` - Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma	Phase 1/Phase 2
	Completed	`NCT00462423` - Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study	Phase 2